Francesco Bibbiani Selected Research

rufinamide

1/2019	Evaluation of long-term safety, tolerability, and behavioral outcomes with adjunctive rufinamide in pediatric patients (≥1 to <4 years old) with Lennox-Gastaut syndrome: Final results from randomized study 303.
4/2017	Dosing considerations for rufinamide in patients with Lennox-Gastaut syndrome: Phase III trial results and real-world clinical data.
5/2016	Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study.
2/2011	A randomized, double-blind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures.
1/2011	Bioavailability of three rufinamide oral suspensions compared with the marketed 400-mg tablet formulation: results from a randomized-sequence, open-label, four-period, four-sequence crossover study in healthy subjects.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Francesco Bibbiani Research Topics

Disease

6	Seizures (Absence Seizure) 01/2019 - 01/2011
5	Dyskinesias (Dyskinesia) 10/2008 - 10/2002
4	Lennox Gastaut Syndrome 01/2019 - 01/2011
3	Parkinson Disease (Parkinson's Disease) 01/2012 - 08/2005
2	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 01/2022 - 12/2020
2	Epilepsy (Aura) 01/2017 - 05/2016
2	Fatigue 09/2015 - 02/2011
2	Dizziness (Lightheadedness) 09/2015 - 02/2011
2	Nausea 05/2011 - 02/2011
1	Disease Progression 01/2022
1	Body Weight (Weight, Body) 05/2016
1	Idiopathic Generalized Epilepsy 09/2015
1	Alzheimer Disease (Alzheimer's Disease) 05/2011
1	Diarrhea 05/2011
1	Vomiting 05/2011
1	Diplopia (Double Vision) 02/2011
1	Sleepiness 02/2011
1	Tremor (Tremors) 10/2008
1	Huntington Disease (Huntington's Disease) 01/2003
1	Movement Disorders (Movement Disorder) 10/2002

Drug/Important Bio-Agent (IBA)

5	rufinamide FDA Link 01/2019 - 01/2011
4	Levodopa (L Dopa)FDA LinkGeneric 10/2008 - 10/2002
3	perampanelIBA 01/2017 - 01/2012
3	Pharmaceutical PreparationsIBA 01/2017 - 01/2003
3	Serotonin (5 Hydroxytryptamine)IBA 10/2008 - 10/2002
2	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 10/2008 - 10/2002
2	Dopamine (Intropin)FDA LinkGeneric 08/2005 - 03/2005
1	Nonsense Codon (Nonsense Mutation)IBA 01/2022
1	atalurenIBA 01/2022
1	deflazacortIBA 12/2020
1	Immunoglobulin E (IgE)IBA 09/2015
1	Excitatory Amino Acid AntagonistsIBA 01/2012
1	propionic acid (potassium propionate)IBA 01/2012
1	entacapone (Comtan)FDA Link 01/2012
1	Donepezil (Aricept)FDA LinkGeneric 05/2011
1	Anticonvulsants (Antiepileptic Drugs)IBA 02/2011
1	SaltsIBA 10/2008
1	Tacrine (Cognex)FDA Link 10/2008
1	5-HT2A Serotonin Receptor (5 HT2A Receptor)IBA 10/2008
1	pimavanserinIBA 10/2008
1	Urea (Carbamide)FDA LinkGeneric 10/2008
1	PyrrolidinesIBA 10/2008
1	AutoreceptorsIBA 08/2005
1	sarizotanIBA 08/2005
1	Serotonin 5-HT1 Receptor AgonistsIBA 08/2005
1	Apomorphine FDA Link 03/2005
1	Glutamate Receptors (Glutamate Receptor)IBA 01/2003
1	Quetiapine Fumarate (Seroquel)FDA Link 10/2002
1	Antipsychotic Agents (Antipsychotics)IBA 10/2002
1	Neurotransmitter Receptors (Neurotransmitter Receptor)IBA 10/2002

Therapy/Procedure

2	Therapeutics 02/2011 - 01/2003
1	Duration of Therapy 03/2005
1	Denervation 01/2003